Page last updated: 2024-09-03

ym 529 and Osteolysis

ym 529 has been researched along with Osteolysis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goto, H; Kanematsu, T; Miki, T; Muguruma, H; Sone, S; Uehara, H; Yano, S; Zhang, H1
Alcalde, RE; Etoh, Y; Kitamura, K; Matsumura, T; Sasaki, A; Suzuki, A; Tanaka, T1

Other Studies

2 other study(ies) available for ym 529 and Osteolysis

ArticleYear
A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
    Clinical & experimental metastasis, 2003, Volume: 20, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Carcinoma, Small Cell; Cell Division; Cytokines; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Humans; Imidazoles; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocyte Depletion; Lymphokines; Male; Mice; Mice, SCID; Osteolysis; Parathyroid Hormone-Related Protein; Peptide Hormones; Severe Combined Immunodeficiency; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003
Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
    International journal of cancer, 1998, Jul-17, Volume: 77, Issue:2

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Imidazoles; Mice; Mice, Nude; Neoplasm Transplantation; Osteolysis

1998